Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer
Table 1
Clinicopathological characteristics of individuals examined in this study.
All cases ()
Cases analyzed by 2DICAL ()
PCa*()
BPH ()
Prostatitis ()
RCC ()
Healthy ()
P value
PCa* ()
Healthy ()
P value
Age
(mean ± SD)
66. 3 ± 7.3
72.3 ± 7.5
65.8 ± 5.9
63.8 ± 8.5
67.2 ± 8.8
0.544****
67.0 ± 7.2
65.1 ± 8.0
0.440****
Stage
I
0
0
II
50
22
III
2
2
IV
2
1
TNM classification**
T1cN0M0
25
10
T2aN0M0
15
7
T2bN0M0
2
1
T2cN0M0
8
4
T3aN0M0
2
2
T4N0M1b
1
1
T4N1M1b
1
0
PSA***
ng/mL
<4
2
11
4
51
2
12
4≦, ≦10
30
10
2
9
<0.001*****
14
3
<0.001*****
10<
22
1
0
0
9
0
Gleason score
5
2
1
6
15
7
7
25
12
8
8
4
9
2
1
10
2
0
Abbreviation: PCa: prostate cancer; according to TNM Classification of Malignant Tumors (International Union Against Cancer), 6th Edition; measured by Tandem R kit before the first treatment; Welch's t-test; Fisher's exact test.
